Business
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral
About this update from Cadrenal Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced the expanded evaluation of tecarfarin for the treatment of patients with antiphospholipid syndrome (APS) who require chronic anticoagulation.\n\n \n \n \n \n \n \n\n \nAPS, formerly known as Hughes Syndrome or Sticky Blood in the United Kingdom, is a disorder of the immune system that causes an increased risk of blood clots. Normally, antibodies protect a person's body from viruses, bacteria, etc., but in APS, antibodies attack the body's healthy cells. High levels of APS antibodies raise the risk of blood clots. The specific antibodies in APS are called 'antiphospholipids' because they attack and damage parts of cells called phospholipids. The damage increases the chance that blood clots will form in both veins and arteries. Patients with APS who receive direct oral anticoagulants (DOACs) may have an increased risk for arterial thrombosis compared with those who receive Vitamin K antagonists (VKAs) such as warfarin, according to a study in the Journal of the American College of Cardiology.\n\"Antiphospholipid syndrome is a rare medical condition and blood clotting disorder affecting approximately 167,000 patients in the United States which currently has no cure. Effective anticoagulation (with blood thinners) should prevent health problems caused by the condition with the goal of treatment to prevent blood clots from forming and to keep existing clots from getting larger,\" commented Douglas Losordo, Chief Medical Officer of Cadrenal Therapeutics. \"However, the only widely prescribed anticoagulant approved for this patient population is warfarin, a 70-year-old drug, which fails to achieve sufficiently reliable anticoagulation due to the way in which it is metabolized. We believe tecarfarin, which is specifically designed to solve warfarin's metabolism problem by using an alternate pathway, could provide improved outcomes for this patient population. Tecarfarin's metabolic pathway is abundant and essentially insaturable, which results in a reliable, stable pharmacokinetic profile.\"\nBased on clinica...